ArticleYonsei medical journal2025
Oral Branched-Chain Amino Acids as a Cost-Effective Option for Managing Hepatic Encephalopathy.
Article in Yonsei medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeOral branched-chain amino acids (BCAAs) may benefit patients with cirrhosis, especially those with hepatic encephalopathy (HE). We analyzed the cost-effectiveness of BCAAs in improving the prognosis of patients with HE. MATERIALS AND
methodsWe compared the total costs and effectiveness of oral BCAA treatment (Scenario 1) versus no BCAA supplementation (Scenario 2) in a virtual cohort of 10000 patients who had experienced HE over a 5-year period. A nested Markov model consisting of four health states (remission, recurrence, stabilization after recurrence, and death) for decompensated cirrhosis was used. Effectiveness was estimated as the cumulative number of HE recurrences and deaths. Additionally, the number of life-years and quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (ICER) were analyzed. Deterministic and probabilistic sensitivity analyses were also performed.
resultsOral BCAA treatment prevented 34% of HE recurrences and reduced the number of HE-related deaths by 18%. Although patients in the BCAA-treated group spent an additional 4086 USD on average compared with their counterparts in the non-treated group ($27088 vs. $23003), they experienced 0.34 more QALYs (2.77 vs. 2.43) over the 5-year period. The ICER for BCAA treatment was 12017 USD/QALY, indicating the high cost-effectiveness of the therapeutic option. Moreover, the sensitivity analyses showed that its economic feasibility was robust. With the willingness-to-pay threshold set at 1 GDP per capita, the probability of cost-effectiveness of BCAA treatment exceeded 80%.
conclusionOral BCAAs for HE prevention may contribute positively to both the clinical status of the patient and the national healthcare budget.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.